Alpharma gets U.S. rights to Diractin

Idea (Munich, Germany) granted ALO exclusive U.S. rights to commercialize Diractin (formerly IDEA-033) to treat pain associated with osteoarthritis (OA). Idea will fund and conduct two Phase III studies to support an NDA submission planned for late 2009. ALO said the trials of the ketoprofen analgesic in Transfersome gel will begin in 1H08. The deal also gives ALO access to Idea's Transfersome drug delivery platform. ...